Arndt Vogel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arndt Vogel has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anna Dodd
Princess Margaret Cancer Centre, Toronto, ON, Canada
1 shared publication Anna Saborowski
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
1 shared publication- Anudari Zorigtbaatar
Toronto General Hospital, Toronto, ON M5G 2C4, Canada
1 shared publication - Ayelet Borgida
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
1 shared publication Cha Len Lee
Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Ontario, Canada
1 shared publication- Erica S. Tsang
Princess Margaret Cancer Centre, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 31 January 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 80
Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at a large Canadian academic cancer center. We characterized the proportion of targetable alterations, the treatment recommendations generated by a molecular tumor board, targeted therapies received, patient outcomes, and the financing of these treatments. A total of 55 patients with BTC prospectively underwent WGTS to inform clinical care. Of those 55, 28 (51%, 95% CI 38–64%) harbored targetable alterations. Molecular tumor boards recommended consideration of targeted therapies for 43 (78% CI: 66–87%) of 55 cases. Among the 15 patients who progressed to second-line therapy and harbored targetable alterations, 8 received nine targeted therapies. No targeted therapies were funded through the public system, and most therapies were funded through compassionate access programs from companies. These results highlight the challenges and potential for inequities when implementing precision oncology in a publicly funded healthcare system.
- 31 January 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 80
Open AccessMolecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at a large Canadian academic cancer center. We characterized the proportion of targetable alterations, the treatment recommendations generated by a molecular tumor board, targeted therapies received, patient outcomes, and the financing of these treatments. A total of 55 patients with BTC prospectively underwent WGTS to inform clinical care. Of those 55, 28 (51%, 95% CI 38–64%) harbored targetable alterations. Molecular tumor boards recommended consideration of targeted therapies for 43 (78% CI: 66–87%) of 55 cases. Among the 15 patients who progressed to second-line therapy and harbored targetable alterations, 8 received nine targeted therapies. No targeted therapies were funded through the public system, and most therapies were funded through compassionate access programs from companies. These results highlight the challenges and potential for inequities when implementing precision oncology in a publicly funded healthcare system.
- 24 November 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (18) , 2385-2397
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine
IntroductionDespite a rising incidence, biliary tract cancers (BTCs) are still considered a rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to a diagnosis at an advanced or unresectable stage, where curative options are limited.Areas coveredThis review provides an overview of current systemic therapies and emerging novel approaches for BTC. For decades, the combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment. However, since 2020, the diagnostic and therapeutic landscape for BTC has evolved considerably, not only in the first-line setting but also beyond, driven by the development of clinical trials exploring immunotherapy and molecularly targeted agents. Due to the high frequency of targetable genetic alterations in BTC patients, there is a growing emphasis on obtaining tissue or liquid biopsy samples to identify markers like microsatellite instability and other actionable oncogenic driver genes.Expert opinionEarly initiation of systemic therapies in combination with multimodal approaches is essential for maximizing survival outcomes in patients with BTC.
- 24 November 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (18) , 2385-2397
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine
IntroductionDespite a rising incidence, biliary tract cancers (BTCs) are still considered a rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to a diagnosis at an advanced or unresectable stage, where curative options are limited.Areas coveredThis review provides an overview of current systemic therapies and emerging novel approaches for BTC. For decades, the combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment. However, since 2020, the diagnostic and therapeutic landscape for BTC has evolved considerably, not only in the first-line setting but also beyond, driven by the development of clinical trials exploring immunotherapy and molecularly targeted agents. Due to the high frequency of targetable genetic alterations in BTC patients, there is a growing emphasis on obtaining tissue or liquid biopsy samples to identify markers like microsatellite instability and other actionable oncogenic driver genes.Expert opinionEarly initiation of systemic therapies in combination with multimodal approaches is essential for maximizing survival outcomes in patients with BTC.